Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for MODS after ATAAD Repair
NCT03552848Unknown
- Sponsor
- Fujian Medical University
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of human umbilical cord mesenchymal stem cells in multiple organ dysfunction syndrome (MODS) (2 arms), sponsored by Fujian Medical University. Primary endpoints: Survival after intervention at 6 months, Adverse events at 2 years and 2 more. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
multiple organ dysfunction syndrome (MODS)
Beyond the preview
Go deeper on NCT03552848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552848.